NCT04408274

Brief Summary

This study will examine the efficacy of a clinical intervention for improving emotional processing in individuals with MS and TBI.(1)The main outcome measure will be changes in emotional processing measures from pre to post treatment. (2)This study will also assess the impact of the emotional processing intervention on changes in pre and post treatment depression and anxiety, as well as fatigue.(3) This study will additionally measure the impact of the emotional processing intervention on cognitive functioning, specifically processing speed, attention and executive abilities. This will be accomplished through the completion of a neuropsychological battery prior to and following the completion of treatment.(4)Finally, the investigators will measure the impact of the intervention on quality of life and social functioning, utilizing a pre and post treatment assessment consisting of measures of self-efficacy, quality of life, functional abilities, and awareness.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
29

participants targeted

Target at P25-P50 for not_applicable multiple-sclerosis

Timeline
Completed

Started May 2013

Longer than P75 for not_applicable multiple-sclerosis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2017

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

April 17, 2018

Completed
2.1 years until next milestone

First Posted

Study publicly available on registry

May 29, 2020

Completed
Last Updated

May 29, 2020

Status Verified

May 1, 2020

Enrollment Period

4.3 years

First QC Date

April 17, 2018

Last Update Submit

May 28, 2020

Conditions

Keywords

Processing SpeedInterventionMultiple SclerosisTraumatic Brain InjuryCognition

Outcome Measures

Primary Outcomes (1)

  • Change in scores on Facial Expression Identification Task (FEIT)

    The FEIT assesses one's ability to correctly identify and discriminate emotions from faces

    Scores will be assessed at two time-points, baseline (week 1) and post-intervention (week 8)

Secondary Outcomes (2)

  • Change in scores on Emotion Regulation Questionnaire (ERQ)

    Scores will be assessed at two time-points, baseline (week 1) and post-intervention (week 8)

  • Change in scores on Satisfaction with Life Scale (SWLS)

    Scores will be assessed at two time-points, baseline (week 1) and post-intervention (week 8)

Study Arms (2)

Computerized Tests

EXPERIMENTAL
Behavioral: Emotional Processing Training

Placebo Control

PLACEBO COMPARATOR
Behavioral: Placebo Control

Interventions

Computerized Tests
Placebo ControlBEHAVIORAL
Placebo Control

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diagnosis of Multiple Sclerosis or Traumatic Brain Injury
  • Fluent in English
  • processing speed impairment (based on evaluation)

You may not qualify if:

  • currently taking steroids and/or benzodiazepines
  • prior stroke or neurological diease
  • history of significant pyschiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder, Schizophrenia, Epilepsy, Bipolar Disorder
  • significant alcohol or drug abuse history

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kessler Foundation

East Hanover, New Jersey, 07936, United States

Location

MeSH Terms

Conditions

Multiple SclerosisBrain Injuries, Traumatic

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesBrain InjuriesBrain DiseasesCentral Nervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and Injuries

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Director, Traumatic Brain Injury Lab

Study Record Dates

First Submitted

April 17, 2018

First Posted

May 29, 2020

Study Start

May 1, 2013

Primary Completion

August 1, 2017

Study Completion

August 1, 2017

Last Updated

May 29, 2020

Record last verified: 2020-05

Locations